Inhibition of Sodium Glucose Cotransporter 2 (SGLT2) Delays Liver Fibrosis in a Medaka Model of Nonalcoholic Steatohepatitis (NASH)

Overview

Journal FEBS Open Bio

Specialty Biology

Date 2019 Apr 16

PMID 30984539

Citations 6

Authors

Ryo Goto

Kenya Kamimura

Yoko Shinagawa-Kobayashi

Norihiro Sakai

Takuro Nagoya

Yusuke Niwa

Masayoshi Ko

Kohei Ogawa

Ryosuke Inoue

Takeshi Yokoo

Akira Sakamaki

Hiroteru Kamimura

Satoshi Abe

Hiroshi Nishina

Shuji Terai

Affiliations

Soon will be listed here.

Abstract

The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested for its therapeutic effect on NASH; however, no studies to date have demonstrated the preventive effect of an SGLT2 inhibitor on the histological progression of steatosis and fibrosis in a sequential manner in animal models. In the present study, we examined the effect of the SGLT2 inhibitor, tofogliflozin (Tofo), on NASH liver tissue using medaka as an animal model, maintaining a feeding amount and drug concentration in all animal bodies. We generated a medaka NASH model by feeding d-rR/Tokyo medaka a high-fat diet and administered Tofo by dissolving the drug directly in the water of the feeding tank. Thereafter, the effects of Tofo on body weight (BW), liver weight, hepatotoxicity, fatty infiltration, and fibrotic changes in the liver were examined. We report here that SGLT2 is expressed in medaka fish and that Tofo inhibits the accumulation of fatty tissue and delays the progression of liver fibrosis in the medaka NASH model by inhibiting increases in blood sugar, serum lipids, and transaminase, irrespective of changes in BW. These results suggest that Tofo is effective for treating NASH and that the medaka model may be useful for developing new therapeutic drugs for this disease.

Citing Articles

The Role of Solute Carrier Family Transporters in Hepatic Steatosis and Hepatic Fibrosis.

Zhang C, Yang X, Xue Y, Li H, Zeng C, Chen M J Clin Transl Hepatol. 2025; 13(3):233-252.

PMID: 40078199 PMC: 11894391. DOI: 10.14218/JCTH.2024.00348.

Dasatinib and Quercetin as Senolytic Drugs Improve Fat Deposition and Exhibit Antifibrotic Effects in the Medaka Metabolic Dysfunction-Associated Steatotic Liver Disease Model.

Yakubo S, Abe H, Li Y, Kudo M, Kimura A, Wakabayashi T Diseases. 2024; 12(12.

PMID: 39727647 PMC: 11727104. DOI: 10.3390/diseases12120317.

SGLT-2 inhibitors as novel treatments of multiple organ fibrosis.

Hu J, Teng J, Hui S, Liang L Heliyon. 2024; 10(8):e29486.

PMID: 38644817 PMC: 11031788. DOI: 10.1016/j.heliyon.2024.e29486.

Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.

Santos-Laso A, Gutierrez-Larranaga M, Alonso-Pena M, Medina J, Iruzubieta P, Arias-Loste M Biomedicines. 2022; 10(1).

PMID: 35052726 PMC: 8773141. DOI: 10.3390/biomedicines10010046.

Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis.

Lin C, Adhikary P, Cheng K Adv Drug Deliv Rev. 2021; 174:127-139.

PMID: 33857552 PMC: 8217274. DOI: 10.1016/j.addr.2021.04.008.

References

Shinagawa-Kobayashi Y, Kamimura K, Goto R, Ogawa K, Inoue R, Yokoo T . Effect of histidine on sorafenib-induced vascular damage: Analysis using novel medaka fish model. Biochem Biophys Res Commun. 2018; 496(2):556-561. DOI: 10.1016/j.bbrc.2018.01.057. View

Neuschwander-Tetri B . Non-alcoholic fatty liver disease. BMC Med. 2017; 15(1):45. PMC: 5330146. DOI: 10.1186/s12916-017-0806-8. View

Ohki T, Isogawa A, Toda N, Tagawa K . Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including.... Clin Drug Investig. 2016; 36(4):313-9. DOI: 10.1007/s40261-016-0383-1. View

Obata A, Kubota N, Kubota T, Iwamoto M, Sato H, Sakurai Y . Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. Endocrinology. 2015; 157(3):1029-42. DOI: 10.1210/en.2015-1588. View

Vrekoussis T, Chaniotis V, Navrozoglou I, Dousias V, Pavlakis K, Stathopoulos E . Image analysis of breast cancer immunohistochemistry-stained sections using ImageJ: an RGB-based model. Anticancer Res. 2010; 29(12):4995-8. View

Bailey C . Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011; 32(2):63-71. DOI: 10.1016/j.tips.2010.11.011. View

Nakano S, Katsuno K, Isaji M, Nagasawa T, Buehrer B, Walker S . Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. J Clin Exp Hepatol. 2015; 5(3):190-8. PMC: 4632078. DOI: 10.1016/j.jceh.2015.02.005. View

Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K . Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care. 2017; 40(10):1364-1372. DOI: 10.2337/dc17-0518. View

Althoff T, Hentschel H, Luig J, Schutz H, Kasch M, Kinne R . Na(+)-D-glucose cotransporter in the kidney of Squalus acanthias: molecular identification and intrarenal distribution. Am J Physiol Regul Integr Comp Physiol. 2005; 290(4):R1094-104. DOI: 10.1152/ajpregu.00334.2005. View

10.

Hirose S, Nakajima S, Iwahashi Y, Seo A, Takahashi T, Tamori Y . Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus. Intern Med. 2016; 55(22):3239-3245. PMC: 5173489. DOI: 10.2169/internalmedicine.55.6367. View

11.

Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E . Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci. 2016; 130(3):159-69. DOI: 10.1016/j.jphs.2016.02.003. View

12.

Michelotti G, Machado M, Diehl A . NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013; 10(11):656-65. DOI: 10.1038/nrgastro.2013.183. View

13.

Townsend S, Newsome P . Review article: new treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017; 46(5):494-507. DOI: 10.1111/apt.14210. View

14.

Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley J . Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2011; 1(2):57-92. PMC: 3138482. DOI: 10.1007/s13300-010-0006-4. View

15.

Matsumoto T, Terai S, Oishi T, Kuwashiro S, Fujisawa K, Yamamoto N . Medaka as a model for human nonalcoholic steatohepatitis. Dis Model Mech. 2010; 3(7-8):431-40. DOI: 10.1242/dmm.002311. View

16.

Sumida Y, Yoneda M . Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2017; 53(3):362-376. PMC: 5847174. DOI: 10.1007/s00535-017-1415-1. View

17.

Lallukka S, Yki-Jarvinen H . Non-alcoholic fatty liver disease and risk of type 2 diabetes. Best Pract Res Clin Endocrinol Metab. 2016; 30(3):385-95. DOI: 10.1016/j.beem.2016.06.006. View

18.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

19.

Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K . Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group.... Cardiovasc Diabetol. 2014; 13:65. PMC: 4021346. DOI: 10.1186/1475-2840-13-65. View

20.

. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016; 387(10026):1377-1396. PMC: 7615134. DOI: 10.1016/S0140-6736(16)30054-X. View